Sandra Milligan, Organon R&D chief
Merck’s women’s health spinoff Organon looks for pharmaceuticals, diagnostics, devices to fill out its pipeline
Sandra Milligan, Organon’s head of R&D, sometimes wishes the women’s health spinoff was an oncology company.
In cancer, the regulatory path is well-trodden. There are …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
